<DOC>
	<DOCNO>NCT02771197</DOCNO>
	<brief_summary>AML common acute leukemia adult . Most patient undergo allogeneic stem cell transplantation possible cure ; however , many patient candidate allogeneic transplant due age , overall health , psychosocial factor , and/or lack available donor . Therefore , patient unable receive therapeutic benefit `` graft-versus-leukemia '' effect donor immune cell . The aim study hopefully break immune tolerance AML cell provide good outcomes patient non-favorable risk AML .</brief_summary>
	<brief_title>Lymphodepletion Anti-PD-1 Blockade Reduce Relapse AML Patient Not Eligible Transplant</brief_title>
	<detailed_description>Non-favorable risk AML patient undergo preparative regimen lymphodepletion Flu/Mel follow autologous transplantation . Anti-PD-1 therapy pembrolizumab begin Day +1 follow stem cell transplantation administer every 3 week total 8 dos . According literature , risk 2-year relapse estimate 60-80 % patient non-favorable risk AML CR-1 . With protocol , investigator hypothesize follow lymphodepleting chemotherapy pembrolizumab , 2-year relapse risk decrease less equal 35 % . The one-sided Wald test 5 % significance level use test hypothesis . The size 20 patient yield power 90.5 % assume actual 2-year leukemia-free survival 60 % .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Nonfavorable risk AML In CR1 subsequent CR Completed least one cycle consolidation chemotherapy Collection least 2x106/kg CD34+ cell KPS 70 % great Received investigational agent within 4 week first dose Prior chemotherapy , radiation therapy within 2 week first dose Hypersensitivity pembrolizumab excipients Received prior therapy antiPD1 , antiPDL1 , antiPDL2 agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
</DOC>